Oral GLP-1 pill yields 12% weight loss in 36 weeks
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Aleniglipron delivered up to 12.1% body-weight loss at the 120mg dose over 36 weeks, versus 0.5% in the placebo arm of a randomized, double-blind, placebo-controlled phase II trial published in Nature Medicine
- The dose response was clear: weight loss reached 9.0% at 45mg, 10.7% at 90mg, and 12.1% at 120mg across 230 adults with obesity or overweight (average age 50) enrolled at 38 U.S. medical centers
- Aleniglipron differs from injectable peptide GLP-1 drugs like semaglutide (Wegovy/Ozempic) because it's a chemically synthesized small molecule taken once daily with or without food — potentially easier to manufacture at scale, with no refrigeration or injection required
- Gastrointestinal side effects were generally mild to moderate and became less frequent as the study progressed; 10.4% of participants discontinued treatment and researchers reported no cases of drug-induced liver injury
- Structure Therapeutics funded the trial, and co-author Robert Kushner, MD, of Northwestern said the phase III trial will slow dose escalation further to improve tolerability
Why it matters: For patients deterred by injections, refrigeration requirements, and limited peptide supply, an oral small-molecule GLP-1 could meaningfully broaden access to obesity treatment — but aleniglipron is still phase II, the 12.1% figure is the top-dose result (not the average), and years of regulatory work remain before any prescription is possible.
Ask SkimNews
